Spectrophotometric Determination of Cilostazol in Tablet Dosage Form
Purpose: To develop simple, rapid and selective spectrophotometric methods for the determination of cilostazol in tablet dosage form. Methods: Cilostazol was dissolved in 50 % methanol and its absorbance was scanned by ultraviolet (UV) spectrophotometry. Both linear regression equation and standard absorptivity were calculated and both methods were validated as per ICH guidelines. Cilostazol was determined in tablet dosage form using these validated methods. Results: The lmax of cilostazol was 258.2 nm in 50 % methanol. Beer-Lambert’s law was obeyed in the concentration range of 0 – 25 μg/ml and standard absorptivity was 420.2 dL.g-1.cm-1 . The numerical values for all the validation parameters were within acceptable limits. The results of cilostazol tablet determination by linear regression equation and standard absorptivity methods indicate purity of 100.0 - 102.4 and 98.7 - 101.1 % with standard deviations of 0.611 and 0.592, respectively. Comparing the methods at 99 % confidence limit, the F-test value was found to be 1.065. Conclusion: These validated methods may be useful for routine analysis of cilostazol as bulk drugs, in dosage forms as well as in dissolution studies in the pharmaceutical industry.
Keywords: Cilostazol tablets, UV spectrophotometry, Linear regression equation, Standard absorptivity.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.